Rotigotine as Pharmacological Augmentation Strategy of Early Rehabilitation of Acute Ischemic Stroke Patient

Sabrina Anticoli¹**, Maria Cristina Bravi¹, Antonio Siniscalchi² and Francesca Romana Pezzella¹

¹Emergency Department, Azienda Ospedaliera San. Camillo-Forlanini, Circonvallazione Gianicolense, Rome
²Department of Neurology, Annunziata Hospital*, Via F. Migliori, Cosenza, Italy

Letter to Editor

Early rehabilitation in stroke patient is generally regarded as a key strategy to improve clinical outcome and patient's quality of life. Based on theoretical considerations of brain plasticity and experimental studies pharmacological augmentation of stroke rehabilitation might be a reasonable intervention to further improve stroke patient prognosis. Rotigotine with transdermal delivery system continuous over 24 hrs that provides an exciting and important opportunity to manipulate the brain's pharmacological environment at a time when physiological remodeling of the brain is occurring through conventional rehabilitation treatments [1]. Understanding the relationship between pharmacologically primed neuroplasticity and practice dependent neuroplasticity is of major scientific interest in understanding how the brain adapts to injury. Some previous studies have suggested that levodopa in combination with physiotherapy may have a positive effect on motor deficits following stroke [2,3].

The aim of this study is to evaluate the functional outcome and the possible adverse events in early start (within 24 hr on stroke unit admission) treatment of rotigotine patch [1] on motor deficits following stroke of middle cerebral artery of both hemisphere. We summarize here our experience with rotigotine patches 2 mg/24 hrs as pharmacological augmentation strategy in early rehabilitation of acute ischemic stroke patient on motor recovery after stroke. We included 40 consecutive patients with acute stroke confirmed by Computed Tomography (CT) scan and MRI. All patients provided written informed consent before participating to the observation.

We limited the observation to a small group of patients with acute ischemic stroke resulting in a severe hemiparesis/hemiplegia (NIHSS score on motor item range 3-4) with premorbid mRankin=0. Exclusion criteria were as follows: A pre-existing neurological condition (e.g., dementia, Parkinson's disease, multiple sclerosis) that would confound cognitive or motor assessments; acute concomitant illness (e.g., infection, unstable angina, myocardial infarction or heart, respiratory, renal or liver failure); systolic blood pressure <120 mmHg and/or diastolic <70 mmHg (as dopamine agonists may lead to postural hypotension, especially during dose escalation); exposure to any other investigational drug within 30 days of enrollment in the study; presence of clinically significant drug or alcohol abuse within the previous 6 months; pregnancy and no r-TPA treatment.

Each patient received 30 min of rehabilitation twice a day within 24 hrs stroke onset and stroke unit standard care. Treatment with rotigotine patches 2 mg daily was started within 24 hrs stroke onset as well. We included 40 consecutive patients, with acute stroke confirmed by CT scan and MRI. Sixteen patients were treated with rotigotine and physiotherapy while 24 patients were treated only with physiotherapy. The groups were homogeneous by gender, age and NIHSS score. In the rotigotine group were selected 16 patients (12 F, 4 M) mean age 79.66 ± 5.97, NIHSS score on admittance to the stroke unit was 16.20 ± 4.79, with motor items score being 3 or 4. In the not-Rotigotine group were selected 24 patients (15 F, 9 M) media age 79.26 ± 9.19, mean NIHSS score on admittance to the stroke unit was 15.04 ± 4.30 with motor item score being 2 or 4. After seven days, in the Rotigotine group, global mean NIHSS score was 12.20 ± 4.22 with more than 50% (11 patients) showing an improvement of motor item score (P<0.05 using paired Student t-Test). In the not-Rotigotine group global mean NIHSS score was 13.08 ± 4.43; 9 patients showed an improvement of motor item score (P=NS). There were no serious adverse events using the patch that was well tolerated. The increase in motor outcome was significantly higher in Rotigotine-group than not Rotogotine that were treated only with physiotherapy.

Previously, Gorgoraptis et al. reported that no significant improvement in motor performance was observed in poststroke patients in treatment with rotigotine without physiotherapy. Furthermore, in this study the patients were eligible only if stroke onset was at least 9 days before the first assessment session [4]. Based on our experience rotigotine in combination with early physiotherapy may enhances motor recovery after stroke. The final evaluation was carried out after only six days from the ischemic event in agreement with the time of hospitalization in the Stroke Unit. It was used the NIHSS because is of easy administration by the same personnel of Stroke Unit. The scale of mRankin which assesses the overall functional capacity of the patient is not valid in identifying small changes in motor skills. The limits of the study are the small number of the sample; do not have been carried out in blind and not to be a randomized trial. Further randomized and blind study, using more sensitive scales such us the Fugl-Meyer scale and a follow-up of the patients are needed to confirm these data.

References

*Corresponding authors: Sabina Anticoli, Stroke Unit, Emergency Department, Azienda Ospedaliera S. Camillo-Forlanini, Circonvallazione Gianicolense, Rome, Italy. Tel: +390658703313; E-mail: sabrina.anticoli@tin.it

Received February 01, 2017; Accepted February 23, 2017; Published February 27, 2017.


Copyright: © 2017 Anticoli S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.